Clinical Transplantation · 1998 · 13 citations · 9 references
MedicineHematologyNephrologyKidney TransplantationTransplant ImmunologyTransplant SurgeryAbo-incompatible Kidney TransplantationAllograft RejectionDonor-recipient CompatibilityHistocompatibilityHla MatchingHla TypingDonor HistocompatibilityHla Antigen MatchingHla Matching In TransplantationHuman Leukocyte Antigen AntibodiesHuman Leukocyte AntigensLiving Donor CompatibilityMixed Lymphocyte ReactionTransplantation Compatibility
We achieved success in ABO-incompatible renal allografting after removing anti-A and/or anti-B antibodies from the recipient's plasma using double filtration plasmapheresis (DFPP). We report here the results of our initial 2 cases. Case 1 was a 40-yr-old female whose blood group was A+. The donor was her younger brother, a 37-yr-old male, whose blood group was B+. The human lymphocyte antigens (HLAs) were one haplotype identical, and the stimulation index of the mixed lymphocyte culture (MLC-SI) was 34. Case 2 was a 28-yr-old male whose blood group was B+. The donor was his father, a 58-yr-old male, whose blood group was AB+. The HLAs were one-haplo-type identical as well, and the MLC-SI was 71. We carried out 4 sessions of DFPP pre-operatively; i.e. on days -6, -4, -2 and -1. 2.5 1 of plasma were treated with 500 ml of 4.4% plasma protein fraction in each procedure. The pre-operative target titer of anti-A/B antibody, measured by the saline tube test, was set at less than x 8. We also used 5 kinds of immunosuppressants. Cyclosporine was administered on day -2 beginning with 8 mg/kg/d, and its dose was modified according to the trough level. 500 mg of methylprednisolone were administered intravenously during the operation, and prednisolone was started on day 1 with 60 mg/d and tapered. Azathioprine was started on day -2 with 2 mg/kg/d for 7 d and 1 mg/kg/d thereafter. 5 mg/kg/d of gusperimus was given intravenously from day 0 for 5 d. 30 mg/kg/d of ALG was given intravenously from day 0 for 14 d. Along with these immunosuppressants, 0.1 mg/kg/h of nafamostat mesilate was administered intravenously from day 0 for 3 d, and 4 mg/kg/d of ticlopidine was given orally from day 3. X-Ray irradiation to the renal graft was not done. Following splenectomy standard renal allografting was performed. In Case 1, the titer of anti-B antibody was reduced from x 16 to x 4. In Case 2, the titer of anti-A antibody was reduced from x 32 to x 4. The post-operative courses of these 2 cases were satisfactory. Although our experience is limited, ABO incompatible kidney transplantation can safely be performed using DFPP.
9
Harrison's Principles of Internal Medicine.
Annals of Internal Medicine · 1988 · 12.6K citations
EXPERIENCES WITH RENAL HOMOTRANSPLANTATION IN THE HUMAN: REPORT OF NINE CASES 1
David M. Hume, John P. Merrill, Benjamin F. Miller et al. · Journal of Clinical Investigation · 1955 · 625 citations · Full text
Medicine, Nephrology, Surgery +12
Kidney Transplantation: Principles and Practice
Clyde F. Barker · Archives of Surgery · 1995 · 106 citations
Medicine, Nephrology, Surgery +12
Splenectomy As a Prerequisite for Successful Human Abo-incompatible Renal-transplantation
Guy P. Alexandre, Yves Pirson, Jean‐Paul Squifflet et al. · Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) · 1985 · 93 citations
Medicine, Hematology, Surgery +11